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1. Introduction 
Solid dispersion is one of the most efficient techniques to improve the dissolution rate of 
poorly water-soluble drugs, leading to an improvement in the relative bioavailability of 
their formulations. At present, the solvent method and the melting method are widely used 
in the preparation of solid dispersions. In general, subsequent grinding, sieving, mixing and 
granulation are necessary to produce the different desired formulations.  
The spherical agglomeration technique has been used as an efficient particle preparation 
technique developed by Kawashima in the 1980s (Kawashima et al., 1994). Initially, 
spherical agglomeration technique was used to improve powder flowability, packability, 
and compressibility (Usha et al. 2008; Yadav and Yadav, 2008; Bodmeier and Paeratakul et 
al., 1989). Then polymers were introduced in this system to modify their release (Di Martino 
et al., 1999). Currently, this technique is used more frequently for the solid dispersion 
preparation of water-insoluble drugs in order to improve their solubility, dissolution rate 
and simplify the manufacturing process (Cui et al., 2003, Tapas et al. 2009, 2010). Spherical 
crystallization has been developed by Yoshiaki Kawashima and co-workers as a novel 
particulate design technique to improve processibility such as mixing, filling, tableting 
characteristics and dissolution rate of pharmaceuticals (Kawashima et al., 1974, 1976, 1981, 
1982, 1983, 1984, 1985, 1989, 1991, 1994, 1995, 2002, 2003). The resultant crystals can be 
designated as spherical agglomerates (Kulkarni and Nagavi, 2002). Spherical crystallization 
is an effective alternative to improve dissolution rate of drugs (Sano et al., 1992). Now days 
functional drug devices such as microspheres, microcapsules, microballoons and 
biodegradable nanospheres were developed using the emulsion solvent diffusion 
techniques involving the introduction of a functional polymer into the system (Di Martino et 
al., 1999; Marshall and York, 1991; Garekani and Ford, 1999). This can be achieved by 
various methods such as  
1. Spehrical Agglomeration (SA) 
2. Quasi Emulsion Solvent Diffusion (QESD) 
3. Ammonia Diffusion System (ADS) 
4. Neutralization (NT) 
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Out of which first two are the most common methods in practice.  
In the spherical crystallization process, crystal formation, growth and agglomeration occur 
simultaneously within the same system. In this method, a third solvent called the bridging 
liquid is added in a smaller amount to purposely induce and promote the formation of 
agglomerates. Crystals are agglomerated during the crystallization process and large 
spherical agglomerates are produced. A near saturated solution of the drug in a good 
solvent is poured into a poor solvent. The poor and good solvents are freely miscible and 
the “affinity” between the solvents is stronger than the affinity between drug and good 
solvent, leading to precipitation of crystals immediately. Under agitation, the bridging 
liquid (the wetting agent) is added, which is immiscible with the poor solvent and 
preferentially wet the precipitated crystals. As a result of interfacial tension effects and 
capillary forces, the bridging liquid acts to adhere the crystals to one another and facilitates 
them to agglomerate (Fig. 1). 
 
Fig. 1. Two sample particles joined together by a liquid bridge  
In spherical agglomeration method, when a drug solution (in good solvent) was poured into 
a poor solvent under agitation, the drug crystals were formed immediately and 
agglomerated with a bridging liquid dispersed in the poor solvent, because the bridging 
liquid has a preference for wetting the drug crystals. 
Quasi emulsion solvent diffusion method is also known as transient emulsion method. 
Firstly the drug was dissolved in a mixed solvent of good solvent and bridging liquid. 
Because of the increased interfacial tension between the two solvents, the solution is 
dispersed into the poor solvent producing emulsion (quasi) droplets, even though the pure 
solvents are miscible. The good solvent diffuses gradually out of the emulsion droplets into 
the surrounding poor solvent phase, and the poor solvent diffuses into the droplets by 
which the drug crystallizes inside the droplets. The method is considered to be simpler than 
the SA method, but it can be difficult to find a suitable additive to keep the system 
emulsified and to improve the diffusion of the poor solute into the dispersed phase. 
Especially hydrophilic/hydrophobic additives are used to improve the diffusion 
remarkably. In this method the shape and the structure of the agglomerate depend strongly 
on the good solvent to poor solvent ratio and the temperature difference between the two 
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solvents when the drug solution was introduced into the poor solvent under certain 
temperature and stirring, the drug solution was dispersed immediately to form quasi o/w 
emulsion droplets, the emulsion droplets were gradually solidified, forming spherical 
agglomerates along with the diffusion of the good solvent from the droplets into the poor 
solvent. 
Spherical agglomeration has got more importance than other methods because it is easy to 
operate and the selection of the solvents is easier than in the other methods. Quasi emulsion 
solvent diffusion method has the second importance. 
An ammonia diffusion system is applicable to amphoteric drug substances. In this method, 
the mixture of three partially immiscible solvent i.e. acetone, ammonia water, 
dichloromethane was used as crystallization system. In this system ammonia water acted as 
bridging liquid as well as good solvent, acetone as the water miscible but poor solvent, thus 
drug precipitated by solvent change without forming ammonium salt. Water immiscible 
solvent such as hydrocarbon or halogenated hydrocarbons e.g. dichloromethane induced 
liberation of ammonia water. 
In neutralization method sodium hydroxide acts as a good solvent and hydrochloric acid as 
a poor solvent or vice-versa. These solutions were added to each other in order to get 
neutralization. The bridging liquid was added drop wise under agitation to form spherical 
agglomerates. 
In this study special attention was given to improving the solubility and dissolution rate of 
poorly water soluble drug carvedilol using quasi emulsion solvent diffusion method. 
Carvedilol (CAR) (fig. 2), (±)-1-(carbazol-4yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-
propanol is an ǂ1, ǃ1 and ǃ2 adrenergic receptor antagonist (Sweetman, 2002). It is used to 
treat mild to moderate essential hypertension, mild to severe heart failure, and patients with 
systolic dysfunction after myocardial infraction. Carvedilol is practically insoluble in water 
and exhibits pH dependent solubility. Its solubility is <1µg/ml above pH 9.0, 23 µg/ml at 
pH 7, and about 100 µg/ml at pH 5 at room temperature. It’s extremely low solubility at 
alkaline pH levels may prevent the drug from being available for absorption in the small 
intestine and colon, thus making it poor candidate for an extended release dosage form. In 
the present study, to overcome the problems related to solubility, dissolution rate, 
flowability, and compressibility, the microspheres having solid dispersions structure of 
Carvedilol were prepared by emulsion solvent diffusion method by using a poloxamer 
(polxamer F68 and poloxamer F127) as a hydrophilic polymer. 
 
Fig. 2. Chemical structure of Carvedilol (CAR) 
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2. Materials and methods 
2.1 Materials 
Carvedilol was supplied by Dr. Reddy’s Laboratory, Hyderabad, India as a gift sample. 
Poloxamer F68 and F127 were supplied by Lupin Research Park, Pune, India. All other 
chemicals used were of analytical grade. 
2.2 Methods 
Carvedilol (1.0 g) with poloxamer was dissolved in good solvent methanol (12.0 mL). The 
bridging liquid dichloromethane (2.0 mL) was added to it. The resulting solution was then 
poured dropwise in to the poor solvent distilled water (100 mL) containing Aerosil 200 
Pharma (0.1 g). The mixture was stirred continuously for a period of 0.5 h using a controlled 
speed mechanical stirrer (Remi motors, India) at 1000 rpm. As the good solvent diffused into 
the poor solvent, droplets gradually solidified. Finally the coprecipitated microspheres of 
the drug-polymer were filtered through Whatman filter paper (No.1) and dried in desiccator 
at room temperature. The amount of poloxamers was altered to get desired microspheres. 
The composition is given in Table 1. 
 
Composition/Parameters CP681 CP682 CP1271 CP1272 
CAR (g) 1.0 1.0 1.0 1.0 
Methanol (ml) 12.0 12.0 12.0 12.0 
DCM (ml) 2.0 2.0 2.0 2.0 
Water (ml) 100 100 100 100 
Poloxamer F68 (g) 1.5 3.0 -- -- 
Poloxamer F127 (g) -- -- 1.5 3.0 
Aerosil 200 pharma (g) 0.1 0.1 0.1 0.1 
Stirring speed (rpm) 1000 1000 1000 1000 
Table 1. Composition of spherical crystals  
2.2.1 Drug content study 
The drug content study of agglomerates was determined by dissolving 100 mg of crystals in 
3 ml methanol and diluting further with distilled water (100 ml) followed by measuring the 
absorbance of appropriately diluted solution spectrophotometrically (PharmaSpec UV-1700, 
UV-Vis spectrophotometer, Shimadzu) at 286 nm. 
2.2.2 Fourier Transform Infrared Spectroscopy (FTIR) 
The FTIR spectra of powder CAR, and their agglomerates were recorded on an FTIR 
spectrophotometer (JASCO, FTIR V-430 Plus). 
2.2.3 Differential Scanning Calorimetry (DSC) 
DSC analysis was performed using a DSC 823 calorimeter (Mettler Toledo model) operated 
by STARe software. Samples of CAR and its agglomerates were sealed in an aluminium 
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crucible and heated at the rate of 10 °C/min up to 300 °C under a nitrogen atmosphere (40 
ml/min). 
2.2.4 Powder X-ray diffraction studies 
Powder X-ray diffraction patterns (XRD) of the CAR and its spherical agglomerates were 
monitored with an x-ray diffractometer (Philips Analytical XRD) using copper as x-ray 
target, a voltage of 40 KV, a current of 25 mA and with 2.28970 Å wavelength. The samples 
were analyzed over 2θ range of 10.01-99.990 with scanning step size of 0.020 (2θ) and scan 
step time of 0.8 second. 
2.2.5 Scanning electron microscopy 
The surface morphology of the agglomerates was accessed by SEM. The crystals were 
splutter coated with gold before scanning. 
2.2.6 Micromeritic properties 
The size of agglomerates was determined by microscopic method using stage and eyepiece 
micrometers. The shape of the agglomerates was observed under an optical microscope (×60 
magnification) attached to a computer. Flowability of untreated carvedilol and agglomerates 
was assessed by determination of angle of repose, Carr’s index (CI) and Hausner’s ratio 
(HR) (Wells, 2002). Angle of repose was determined by fixed funnel method (Martin et al., 
2002). The mean of three determinations was reported. The CI and HR were calculated from 
the loose and tapped densities. Tapped density was determined by tapping the samples into 
a 10 ml measuring cylinder. The CI and HR were calculated according to the following 
equation 1 and 2. 
 
Tapped density – Bulk density
C.I. = ×100
Tapped density
 (1) 
 
Tapped density
H.R. =
Bulk density
 (2) 
2.2.7 Solubility studies 
A quantity of crystals (about 100 mg) was shaken with 10 mL distilled water in stoppered 
conical flask at incubator shaker for 24 h at room temperature. The solution was then passed 
through a whatmann filter paper (No. 42) and amount of drug dissolved was analyzed 
spectrophotometrically. 
2.2.8 Dissolution rate studies 
The dissolution rate studies of carvedilol alone and its spherical agglomerates were 
performed in triplicate in a dissolution apparatus (Electrolab, India) using the paddle 
method (USP Type II). Dissolution studies were carried out using 900 ml of 0.1N HCl (pH 
1.2) at 37 ± 0.5 0C at 50 rpm as per US FDA guidelines (U.S. Food and drug administration 
[USFDA], 2010 and Bhutani et al., 2007.). 12.5 mg of carvedilol or its equivalent amount of 
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spherical agglomerates were added to 900 ml of 0.1N HCl (pH 1.2). Samples (5 ml) were 
withdrawn at time intervals of 10, 20, 30, and 60 min. The volume of dissolution medium 
was adjusted to 900 ml by replacing each 5 ml aliquot withdrawn with 5 ml of fresh 0.1N 
HCl (pH 1.2). The solution was immediately filtered, suitably diluted and the concentrations 
of carvedilol in samples were determined spectrophotometrically at 286 nm. The results 
obtained from the dissolution studies were statistically validated using ANOVA. 
2.2.9 Dissolution efficiency studies 
The dissolution efficiency (DE) of the batches was calculated by the method mentioned by 
Khan (Khan, 1975). It is defined as the area under the dissolution curve between time points 
t1 and t2 expressed as a percentage of the curve at maximum dissolution, y100, over the 
same time period or the area under the dissolution curve up to a certain time, t, (measured 
using trapezoidal rule) expressed as a percentage of the area of the rectangle described by 
100% dissolution in the same time. DE60 values were calculated from dissolution data and 
used to evaluate the dissolution rate (Anderson et al., 1998).  
 0
2 1
Dissolution Efficiency = 100 
100( )
t
ydt
y t t
×
−

 (3) 
3. Result and discussion 
3.1 Preparation of spherical crystals 
A typical spherical crystallization system involved a good solvent, a poor solvent for a drug 
and a bridging liquid. The selection of these solvent depends on miscibility of the solvents 
and solubility of drug in individual solvents. Accordingly acetone, dichloromethane, water 
were selected as a good solvent, bridging liquid, and poor solvent, respectively. CAR is 
soluble in methanol, but poorly soluble in water. Also it is soluble in dichloromethane 
which is immiscible in water. Hence, this solvent system was used in the present study. 
When drug polymer solution was poured into the poor solvent under agitation at selected 
temperature, the drug polymer solution became immediately semitransparent due to the 
presence of small sized emulsion droplets. Gradually emulsion droplets solidified along 
with diffusion of the good solvents, as bridging liquid dichloromethane was commixed with 
good solvent, when the good solvent in the droplets diffused into the poor solvent, the 
residual dichloromethane in the droplets bridged the Aerosil, coprecipitated drug, and 
polymer to form spherical crystals. The Aerosil acts as a dispering agent and mass 
compactor, because coacervation droplets formed from the drug-polymer droplets during 
the solidifying period were sticky and readily coalesced, while the introduction of Aerosil 
efficiently prevented coalescence and produced compact spherical crystals. 
3.2 Optimization of process variables for preparation of spherical crystals 
To optimize the Carvedilol spherical crystallization by methanol, water, dichloromethane 
solvent system following parameters considered amount and mode of addition of bridging 
liquid, stirring speed and temperature. (Table 2). 
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S.No. Parameter Variables Observation 
1 Conc. of Bridging Liquid 
(Dichloromethane) 
1 ml No agglomeration 
2 ml Agglomeration 
3 ml No agglomeration 
2 Agitation speed 800 rpm Spherical but large 
1000 rpm Spherical  
1200 rpm Irregular shape and small 
3 Agitation time 15 min Incomplete agglomerates 
30 min Spherical agglomerates 
4 Mode of addition of bridging 
liquid 
Whole at a time Crystals of irregular geometry 
Drop wise  Spherical agglomerates 
Table 2. Parameters affecting spherical agglomeration 
3.3 Drug content study 
Percent drug content was found to be in the range of 92.12±1.60 to 94.4±2.37 (Table 3). 
3.4 Micromeritic properties 
Pure CAR could not pass through the funnel during the angle of repose experiment which 
could be due to the irregular shape and high fineness of the powder, which posed hurdles in 
the uniform flow from the funnel. It exhibited poor flowability and packability as indicated 
by Hausner ratio (1.52) and Carr’s Index (34.37%). All agglomerates showed excellent 
flowability and packability (Angle of repose: 23-280; Carr’s Index: 15-18%; Hausner ratio: 
1.13-1.17) when compared to pure CAR. The improved flowability of agglomerates may be 
due to good sphericity and larger size of agglomerates. During the tapping process, smaller 
agglomerates might have infiltrated into the voids between larger particles, which could 
result improved packability (lower CI). The results of micromeritic properties are shown in 
Table 3. 
S.No. Samples Drug Content Carr’s Index
Hausner 
Ratio 
Angle of 
Repose 
Particle Size 
(µm) 
Aqueous 
Solubility 
(µgmL-1) 
1. CAR 100.0±0.0 34.37±1.79 1.52±1.26 --- 71.55±5.37 21.0 ± 0.51 
2. CP681 94.4±2.37 17.53±1.49b 1.15±2.67b 27.12±2.43 112.7±31.26b 32.20 ± 1.32 
3. CP682 92.31±2.02 15.64±1.43b 1.13±2.21b 25.36±0.67 136.43±18.57b 39.04 ± 1.65b 
4. CP1271 94.19±1.15 18.63±2.90b 1.17±1.82b 28.42±0.23 88.92±25.38b 58.08 ± 1.28b 
5. CP1272 92.12±1.60 17.24±1.87b 1.14±1.53b 23.05±0.89 102.03±20.11b 64.25 ± 1.31b 
aMean ± SD, n = 3; bSignificantly different compared to pure CAR (p<0.05). 
Table 3. Micromeritics, Drug Content, Particle size, aqueous solubility data of carvedilol and 
its spherical crystals 
3.5 FTIR, DSC and powder X-ray studies 
The FTIR spectra of CAR as well as its spherical crytals are presented in Figure 3. FTIR of 
CAR showed a characteristic peaks at 3343.96 (N-H str. Aromatic Amines), 3062.41 (C-H str.  
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Fig. 3. FTIR spectra of (A) – Carvedilol, (B) – CP682, (C) – CP1272 
Aromatic Hydrocarbon), 2923.56 (C-H str. in –CH3/ –CH2), 1592.91 (C=C str. Aromatic), 
1253.5, 1214.93, 1099.23 (C-O str. in Ar C=C-O-C) cm-1. There was no considerable change in 
the IR peaks of the spherical agglomerates when compaired with pure CAR, which revealed 
that no chemical interaction had occurred between drug and polymer during agglomeration 
process. 
Figure 4 shows the DSC thermogram of pure CAR and its spherical crystals. DSC 
thermogram of CAR showed endothermic peak at 120.470C, which represented melting of 
carvedilol. There was negligible change in the melting point endotherms of prepared 
spherical crystals compared to pure drug (CP682 = 115.470C, CP1272 = 118.670C). The 
endotherms at 57.050C and 59.070C ascribed to the melting of Poloxamer F68 and Poloxamer 
F127 respectively. This observation further supports the IR spectroscopy results, which 
indicated the absence of any interactions between the drug and additives used in the 
preparation. However, there was a decrease, although very small, in the melting point of the 
drug in the spherical crystals compared to that of pure carvedilol. This indicates the little 
amorphization of carvedilol when prepared in the form of spherical crystals. 
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Fig. 4. DSC thermogram of (A) – Carvedilol, (B) – CP682, (C) – CP1272. 
The XRD patterns of CAR shown in figure 5. The intense peaks at 2θ of 26.160, 27.480, 36.470 
and 39.340 with peak intensities (counts) 310, 256, 228 and 135 respectively obtained from 
CAR confirmed the crystalline form of CAR. The PXRD patterns of CAR spherical crystals 
could be distinguished from the pure CAR. Peaks at around 8.4, 17, 220 2θ confirms the 
change in crystal arrangements of CAR in its spherical crystal form. 
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Fig. 5. XRD patterns of (A) – Carvedilol, (B) – CP682, (C) – CP1272. 
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3.6 Scanning electron microscopy 
The results of surface morphology studies are shown in Figure 6. The SEM results revealed 
the spherical structure of agglomerates. The surface morphology studies also revealed that 
the agglomerates were formed by very small crystals, which were closely compacted into 
spherical form. These photo-micrographs show that the prepared agglomerates were 
spherical in shape which enabled them to flow very easily. 
 
 
A 
 
B 
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C 
Fig. 6. SEM of (A) – Carvedilol, (B) – CP682, (C) – CP1272 
3.7 Dissolution rate studies 
The dissolution curves of pure carvedilol and its spherical crystals in 0.1 N HCl (pH 1.2) are 
shown in fig. 7. The release rate profiles were expressed as the percentage drug released vs. 
time. Table 4 shows % drug dissolved in 1h (DP60) and dissolution efficiency values at 30 
min (DE30) for carvedilol and its spherical crystals. These values are tested statistically 
through one way ANOVA and are found significantly different (p<0.05) from pure 
carvedilol. As indicated carvedilol was dissolved more than 80% from spherical crystals 
CP681, CP1271 and CP1272 after 1h and more than 90% from spherical crystal CP682 while 
the pure CAR powder was just dissolved 34.37% at comparable time. The results revealed 
that the spherical crystals caused significant increase (P<0.05) in drug release compared to 
the pure drug. Enhancement in dissolution rate of spherical agglomerates as compared to 
pure drug may be due the presence of hydrophilic polymer, Poloxamer. The mechanism  
 
Sample Carvedilol Release after 1h Dissolution Efficiency at 30 min 
CAR 34.37±0.19 20.56±0.09 
CP681 83.42±0.25b 66.12±0.31b 
CP682 95.52±0.25b 70.63±1.38b 
CP1271 82.26±0.96b 65.90±0.14b 
CP1272 84.42±0.07b 67.39±0.39b 
aMean ± SD, n = 3 
bSignificantly different compared to carvedilol (p < 0.05). 
Table 4. Drug Release and Dissolution Efficiencya 
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Fig. 7. Dissolution profile of CAR and its agglomerates. (Mean ±SD, n = 3.) 
behind the greater solubility and dissolution of CAR from its agglomerated form may 
resemble the solid dispersion mechanism despite the larger particle size of agglomerates. 
This effect may be due to improved wettability of the surface of agglomerates by the 
adsorption of poloxamer onto the surfaces of crystals. These results confirm that the 
dissolution rate of carvedilol was increased in form of spherical crystals when compared to 
its pure form. 
4. Conclusion 
CAR-poloxamer spherical crystals were prepared successfully by ESD method. The 
resultant crystals have the desired micromeritic properties, such as flowability and 
packability. In the present investigation Poloxamer F68 and Poloxamer F127 has 
significantly improved dissolution rate of carvedilol. However in vivo bioavailability studies 
are required to ensure whether, the results obtain in this investigation can be extrapolated to 
the in vivo conditions.  
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